November marks Diabetic Eye Disease Awareness Month, highlighting the silent vision risks of diabetes and the importance of ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...
Zacks Investment Research on MSN
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
ANI Pharmaceuticals’ ANIP rare disease franchise has emerged as a major growth catalyst in 2025, with segment revenues more ...
Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
Kidney disease disproportionately affects Black communities, with Black Americans nearly four times as likely to develop ...
SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback